Veritas Confirms Readiness for Human Trials of CTL-X for Pain; Projected to Start Early Next Month
November 08, 2018 08:30 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP) (“Veritas” or the “Company”) is pleased to announce that, despite the...
Veritas Pharma Provides Corporate Update on Q1 2018
February 21, 2018 03:10 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Feb. 21, 2018 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) is pleased to provide an official corporate...
Veritas’ Research Arm Cannevert Therapeutics Signs Letter of Intent with Fundación de Investigación (FDI) of Puerto Rico USA to Begin Human Trials of Its Lead Cannabis Strain for Pain
November 20, 2017 03:05 ET
|
Veritas Pharma Inc.
VANCOUVER, British Columbia, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt:2VP), (“Veritas” or the “Company”) announces that its research arm, Cannevert...